HOUSTON — Oncolin Therapeutics, Inc., (OTCBB:OCOL) announces that its new Super Cell Blocker, ONC-127, has been effective in treating animals that have been implanted with human tumors in their brains. This technology has extended the life of animals in a preclinical environment.
The Super Cell Blocker, ONC-127, drug candidate is a major breakthrough in inhibiting a process known as glycolysis which "starves the tumor" by blocking its ability to provide energy for the cell to live. The founding scientists have designed a drug that passes through the Blood Brain Barrier (BBB) which is the brain's security mechanism that stops most other drugs from reaching the brain in order to target the brain tumor and is also selectively taken up by brain tumor cells. This technology is also applicable to other cancers that have a high sugar uptake such as breast and pancreatic cancers.
This technology is covered under Oncolin's recent exclusive option to license from The University of Texas M.D. Anderson Cancer Center which is one of the world's leading cancer treatment facilities.
About Oncolin Therapeutics, Inc.
Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com.
Safe Harbor Statement
This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin's future business and financial results, refer to Oncolin's Quarterly Report on Form 10-QSB for the quarter ended December 31, 2007 and Annual Report on Form 10-KSB for the year ended March 31, 2007. Oncolin Therapeutics undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.
Oncolin Therapeutics, Inc., Houston J. Leonard Ivins, 832-426-7909 Investors@oncolinthera.com